Glaxo heart drug shown to be safer than rival
‘GlaxoSmithKline’s Arixtra, a treatment of acute coronary syndromes, has been shown in a large study to be as effective as Sanofi-Aventis’ industry standard Lovenox, whilst demonstrating a significantly better safety profile.
This landmark head-to-head trial, evaluated more than 20,000 patients with ACS, and was presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden.
Arixtra was as effective as Lovenox for the primary composite endpoint of preventing death, myocardial infarction, and refractory ischaemia at 9 days (incidence of 5.9% and 5.8%, respectively). Furthermore, Arixtra was associated with a 47% reduction in major bleeding vs. Lovenox in this study.’
Read more at Glaxo heart drug shown to be safer than rival
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax